Lapatinib (GW2016; 0.03-10 µM; 6 hours; BT474 and HN5 cells) treatment inhibits receptor autophosphorylation of EGFR and ErbB-2 in a dose-responsive manner. Phosphorylation of serine 473 of AKT was inhibited by GW2016 in a dose-dependent manner.
Lapatinib (GW2016; 72 hours; HN5, A-43, BT474, N87, and CaLu-3 cells) treatment has a selective inhibition of the proliferation of human tumor cell lines.
Lapatinib (GW2016; 1-10 µM; 72 hours; HN5 cells) treatment results in induces G1 arrest.
Western Blot Analysis
| Cell Line: |
BT474 and HN5 cells |
| Concentration: |
0.03 µM, 0.1 µM, 0.3 µM, 1 µM, 3 µM, or 10 µM |
| Incubation Time: |
6 hours |
| Result: |
Inhibited receptor autophosphorylation of EGFR and ErbB-2 in a dose-responsive manner. Phosphorylation of serine 473 of AKT was also inhibited in a dose-dependent manner.
|
Cell Proliferation Assay
| Cell Line: |
HN5, A-43, BT474, N87, and CaLu-3 cells |
| Concentration: |
|
| Incubation Time: |
72 hours |
| Result: |
Inhibited the growth of tumor cells overexpressing EGFR or ErbB-2.
|
Cell Cycle Analysis
| Cell Line: |
HN5 cells |
| Concentration: |
1 µM, or 10 µM |
| Incubation Time: |
72 hours |
| Result: |
Resulted in induction of G1 arrest.
|